ACORN BIOVENTURES, L.P. 13D and 13G filings for OnKure Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-04-01 11:17 am Purchase | 2026-03-27 | 13G | ONKURE THERAPEUTICS, INC. CLAS OKUR | ACORN BIOVENTURES, L.P. | 3,924,037 9.500% | 1,084,363 (+38.19%) | Filing |
| 2025-05-30 3:57 pm Unchanged | 2025-05-15 | 13D | ONKURE THERAPEUTICS, INC. CLAS OKUR | ACORN BIOVENTURES, L.P. | 2,839,674 22.100% | 0 (Unchanged) | Filing |
| 2025-05-22 4:49 pm Purchase | 2025-05-15 | 13D | ONKURE THERAPEUTICS, INC. CLAS OKUR | ACORN BIOVENTURES, L.P. | 2,839,674 22.100% | 1,400,000 (+97.24%) | Filing |
| 2024-10-09 4:01 pm Purchase | 2024-10-04 | 13G | ONKURE THERAPEUTICS, INC. CLAS OKUR | ACORN BIOVENTURES, L.P. | 1,439,674 11.400% | 1,439,674 (New Position) | Filing |